Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nanologica AB FCF Yield % Related Terms
Nanologica AB FCF Yield % Historical Data
* Premium members only.
The historical data trend for Nanologica AB's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:NICA vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Nanologica AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanologica AB FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanologica AB's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Nanologica AB's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nanologica AB (OSTO:NICA) has a FCF Yield % of -17.30 as of Jul. 14, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nanologica AB and its competitors. According to the industry distribution chart, Nanologica AB ranks #910 out of 1409 companies in the Biotechnology industry, placing it in the top 64.6%.
Is Nanologica AB's FCF Yield % too high?
Nanologica AB's current FCF Yield % is -17.30. Based on the distribution chart, Nanologica AB ranks #910 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanologica AB has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanologica AB's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanologica AB ranks #910 out of 1409 companies for FCF Yield %. This places Nanologica AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nanologica AB and its competitors. Nanologica AB's current FCF Yield % is -17.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanologica AB stock overvalued right now?
Based on GuruFocus' analysis, Nanologica AB (OSTO:NICA) is currently considered Possible Value Trap. The stock's GF Value™ is kr4.24, compared to a current price of kr0.47 — trading 88.8% below its estimated fair value. The current FCF Yield % is -17.30. Nanologica AB's overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nanologica AB (OSTO:NICA), the current FCF Yield % is -17.30 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanologica AB (OSTO:NICA) Overvalued in 2026?
Based on GuruFocus' analysis, Nanologica AB stock appears to be undervalued.
The current stock price of kr0.47 is trading 88.8% below its estimated GF Value™ of kr4.24.
GuruFocus considers Nanologica AB to be Possible Value Trap.
Key valuation signals for OSTO:NICA:
FCF Yield %: -17.30
GF Value™: kr4.24 vs. price of kr0.47 (88.8% below fair value)
No single metric tells the full story. See the OSTO:NICA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells key consumables to pharmaceutical manufacturers. Its products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, it can increase productivity and reduce costs for pharmaceutical manufacturers. The group operates in a world-wide niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
45GF Score
Get the complete analysis for OSTO:NICA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NICA has been successfully added to your 
